16 completed, 2 withdrawn. 18 Phase 3, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 18 | Completed 16, Withdrawn 2 |
| Phase 2 | 5 | Completed 3, Withdrawn 2 |
Follow Novavax: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Immunogenicity of NVX-CoV2705 NVX-CoV2705 - COVID-19, SARS-CoV-2 Infection | Phase 3 | Completed | Sanofi | 676 | 2025-10-09 | 2026-06-05 |
| Lot Consistency Study of COVID-19 and Influenza Combination Vaccine coformulated CIC Vaccine, Fluzone HD trivalent - COVID-19, Influenza | Phase 2 / Phase 3 | Withdrawn | Novavax | 2025-02-01 | 2025-03-11 | |
| A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine CIC Vaccine Co-formulated tNIV2 , SARSCoV-2 rS and Matrix-M Adjuvant, Novavax COVID-19 Vaccine, tNIV Vaccine - COVID-19 | Phase 3 | Completed | Novavax | 9320 | 2024-12-09 | 2026-06-05 |
| Phase 3 Lot Consistency Study of Trivalent Hemagglutinin Nanoparticle Influenza Vaccine tNIV 1 and Matrix-M Adjuvant - COVID-19 | Phase 2 / Phase 3 | Withdrawn | Novavax | 2024-11-01 | 2025-03-11 | |
| A Strain Change Study for SARS-CoV-2 rS Vaccines NVX-CoV2705 Vaccine - Severe Acute Respiratory Syndrome Coronavirus 2 Infection | Phase 3 | Completed | Novavax | 60 | 2024-10-14 | 2025-07-18 |
| Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines NVX-CoV2373 (5μg), NVX-CoV2601 (5μg), NVX-CoV2601(5μg) - COVID-19 | Phase 2 / Phase 3 | Completed | Novavax | 994 | 2023-10-16 | 2024-12-13 |
| A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants. XBB.1.5 Vaccine (Booster), XBB.1.5 Vaccine (single dose) - COVID-19 | Phase 2 / Phase 3 | Completed | Novavax | 660 | 2023-09-07 | 2024-05-30 |
| Phase 3 Adolescent Study for SARS-CoV-2 rS Variant Vaccines NVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine, Prototype/XBB.1.5 Bivalent Vaccine (5 µg) - COVID-19 | Phase 3 | Completed | Novavax | 400 | 2023-08-16 | 2025-07-15 |
| Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA Vaccines NVX-CoV2373, SARS-CoV-2 rS antigen/Matrix-M Adjuvant - COVID-19 | Phase 3 | Completed | Novavax | 147 | 2023-03-28 | 2025-06-26 |
| Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), Placebo - COVID-19 | Phase 2 / Phase 3 | Completed | Novavax | 3600 | 2022-07-22 | 2026-05-22 |
| Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults NVX-Cov2373 - COVID-19, SARS-CoV-2 Infection | Phase 3 | Completed | Novavax | 911 | 2022-07-11 | 2026-04-17 |
| Phase 3 Boosting Study for the SARS-CoV-2 rS Variant Vaccines NVX-CoV2515, NVX-Cov2373, NVX-CoV2373 + NVX-CoV2515 - COVID-19, SARS CoV 2 Infection | Phase 3 | Completed | Novavax | 1340 | 2022-05-25 | 2024-04-23 |
| Phase 3 Boosting Study for the SARS-CoV-2 rS Vaccine NVX-CoV2373, BBIBP-CorV vaccine - Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) | Phase 3 | Completed | Cogna Technology Solutions LLC | 1000 | 2022-03-18 | 2023-08-02 |
| A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), Placebo (Initial Vaccination Period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period) - SARS-CoV Infection, Covid19 | Phase 3 | Completed | Novavax | 33000 | 2020-12-27 | 2023-12-21 |
| A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom SARS-CoV-2 rS/Matrix M1-Adjuvant, Placebo, Licensed seasonal influenza vaccine - SARS-CoV-2 Infection, COVID-19 | Phase 3 | Completed | Novavax | 15185 | 2020-09-28 | 2025-05-08 |
| Phase 3 Pivotal Trial of NanoFlu™ in Older Adults NanoFlu, Fluzone Quadrivalent - Influenza, Human | Phase 3 | Completed | Novavax | 2654 | 2019-10-14 | 2023-05-06 |
| A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization RSV F vaccine with adjuvant, Formulation buffer - Respiratory Syncytial Virus Infections | Phase 3 | Completed | Novavax | 4636 | 2015-12-01 | 2025-05-06 |
| A Study to Evaluate the Efficacy of an RSV F Vaccine in Older Adults RSV-F Vaccine, Phosphate Buffer Placebo - Respiratory Syncytial Virus (RSV) | Phase 3 | Completed | Novavax | 11850 | 2015-11-01 | 2022-07-19 |
COVID-19 (14) · Coronavirus Infections (4) · Influenza, Human (4) · Respiratory Syncytial Virus Infections (1) · Severe Acute Respiratory Syndrome (1)
NVX-CoV2373 adjuvated lipid nanoparticle (9) · Sodium Chloride (3) · Immunization, Secondary (2) · Influenza Vaccines (2) · Adjuvants, Pharmaceutic (1) · BIBP COVID-19 vaccine (1) · Fluzone High-Dose (1) · Matrix-M (1)
United States (12) · Australia (3) · Mexico (3) · United Kingdom (3) · New Zealand (2) · Philippines (2) · South Africa (2) · Spain (2) · Argentina (1) · Bangladesh (1) · Chile (1) · Colombia (1) · Dominican Republic (1) · Guatemala (1) · Honduras (1)
Nawal Al Kaabi (1) · Paul T Heath, MB BS FRACP FRCPCH (1)
PMID 32726529, PMID 34563277, PMID 34800364, PMID 34910859, PMID 36172135, PMID 37099299, PMID 37127523, PMID 37385888, PMID 37652823, PMID 38365482, PMID 38460525, PMID 39052718, PMID 39225478, PMID 39824198, PMID 39884302, PMID 40184816, PMID 41117170, PMID 41455184